Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
A live webcast will be accessible in the Events & Presentations section of the Company’s Investor Relations website at www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website at www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Tel: (301) 838-2591
or
INVESTOR CONTACT:
ICR Westwicke
Office: (443) 213-0505
Email: peter.vozzo@westwicke.com
![](https://ml.globenewswire.com/media/MGI4NDAyZmYtOTA2Yy00OTBmLWE1MTUtOWY1NjRmOTdhMGQ2LTEwMjI1MTU=/tiny/Supernus-Pharmaceuticals-Inc-.png)
Source: Supernus Pharmaceuticals, Inc.